U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H26ClN3O3.ClH
Molecular Weight 404.331
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRUCALOPRIDE HYDROCHLORIDE

SMILES

Cl.COCCCN1CCC(CC1)NC(=O)C2=CC(Cl)=C(N)C3=C2OCC3

InChI

InChIKey=KKMOQGWTJRGLNN-UHFFFAOYSA-N
InChI=1S/C18H26ClN3O3.ClH/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14;/h11-12H,2-10,20H2,1H3,(H,21,23);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H26ClN3O3
Molecular Weight 367.87
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Prucalopride is a novel enterokinetic compound and is the first representative of the benzofuran class. Prucalopride is a potent, selective and specific serotonin 5-HT4 receptor (5-HT4-R) agonist. Prucalopride (Resolor®), a highly selective serotonin 5-HT4 receptor agonist, is indicated in the European Economic Area for the treatment of adults with chronic idiopathic constipation (CIC) in whom laxatives have failed to provide adequate relief.

CNS Activity

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.6 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RESOLOR

Approved Use

Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief

Launch Date

2008
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7 ng/mL
2 mg 1 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PRUCALOPRIDE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
109 ng × h/mL
2 mg 1 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PRUCALOPRIDE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1 day
2 mg 1 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PRUCALOPRIDE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
2 mg 1 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PRUCALOPRIDE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Disc. AE: Nausea, Headache...
Other AEs: Headache, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Nausea (2%)
Headache (1%)
Diarrhea (1%)
Abdominal pain (1%)
Other AEs:
Headache (19%)
Abdominal pain (16%)
Upper abdominal pain (16%)
Lower abdominal pain (16%)
Abdominal tenderness (16%)
Abdominal discomfort (16%)
Epigastric discomfort (16%)
Nausea (14%)
Diarrhea (13%)
Abdominal distension (5%)
Dizziness (4%)
Vomiting (3%)
Flatulence (3%)
Fatigue (2%)
Nausea (2%)
Headache (1%)
Diarrhea (1%)
Abdominal pain (1%)
Headache (19%)
Abdominal pain (16%)
Upper abdominal pain (16%)
Lower abdominal pain (16%)
Abdominal tenderness (16%)
Abdominal discomfort (16%)
Epigastric discomfort (16%)
Nausea (14%)
Diarrhea (13%)
Abdominal distension (5%)
Dizziness (4%)
Vomiting (3%)
Flatulence (3%)
Fatigue (2%)
Sources:
10 mg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
healthy
n = 60
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 1%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Diarrhea 1%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Headache 1%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal pain 1%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Diarrhea 1%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Headache 1%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Diarrhea 13%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Diarrhea 13%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Nausea 14%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Nausea 14%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal discomfort 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal discomfort 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal pain 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal pain 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal tenderness 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal tenderness 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Epigastric discomfort 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Epigastric discomfort 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Lower abdominal pain 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Lower abdominal pain 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Upper abdominal pain 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Upper abdominal pain 16%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Headache 19%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Headache 19%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Fatigue 2%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Fatigue 2%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Nausea 2%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Nausea 2%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Flatulence 3%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Flatulence 3%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Vomiting 3%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Vomiting 3%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Dizziness 4%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Dizziness 4%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal distension 5%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
Abdominal distension 5%
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 47 years (range: 17-95 years)
n = 1251
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 47 years (range: 17-95 years)
Sex: M+F
Population Size: 1251
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >=300 uM]
no [IC50 >=300 uM]
no
no
no
no
no
no
no
no
weak
yes [IC50 38 uM]
weak (co-administration study)
Comment: administered with dextromethorphan; in vivo DDI potential via inhibition of CYP2D6 appears low at the proposed dose
Page: 188.0
yes [IC50 4 uM]
yes [IC50 69 uM]
yes [IC50 7.8 uM]
yes [IC50 9.4 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes [Km 116 uM]
yes [Km 15 uM]
yes
weak (co-administration study)
Comment: co-administration of ketoconazole increased the Cmax and AUCtau of prucalopride at steady state by 38% and 37%, respectively; Administration of erythromycin, probenecid, cimetidine, and paroxetine did not have a significant effect on the PK of prucalopride (<10% change in Cmax and AUC)
Page: 100;187
Tox targets

Tox targets

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Pharmacological treatment of irritable bowel syndrome--from concept to sales.
2002
Prucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants.
2005 Jun
Increased cholinergic contractions of jejunal smooth muscle caused by a high cholesterol diet are prevented by the 5-HT4 agonist--tegaserod.
2006 Feb 23
Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development.
2006 Jan
Fading of 5-HT4 receptor-mediated inotropic responses to 5-hydroxytryptamine is caused by phosphodiesterase activity in porcine atrium.
2006 Jan
Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior.
2006 Jun
Investigation of serotonin receptors in the isolated penile bulb of rats.
2006 Nov-Dec
5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle.
2006 Sep
5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice.
2007 Apr
The serotonin signaling system: from basic understanding to drug development for functional GI disorders.
2007 Jan
Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract.
2007 Jan
Electrophysiological and arrhythmogenic effects of 5-hydroxytryptamine on human atrial cells are reduced in atrial fibrillation.
2007 Jan
Gateways to clinical trials. July-August 2008.
2008 Jul-Aug
Prucalopride: the evidence for its use in the treatment of chronic constipation.
2008 Jun
The long and short of a constipation-reducing medication.
2008 May 29
A placebo-controlled trial of prucalopride for severe chronic constipation.
2008 May 29
New treatments for irritable bowel syndrome in women.
2008 Nov
[Functional and motor gastrointestinal disorders].
2008 Oct
Gateways to clinical trials.
2008 Oct
Gateways to clinical trials.
2008 Sep
Management of constipation in the elderly: emerging therapeutic strategies.
2008 Sep 7
Prucalopride.
2009
Gateways to clinical trials.
2009 Apr
Prucalopride: a new drug for the treatment of chronic constipation.
2009 Aug
Gateways to clinical trials.
2009 Dec
Prucalopride for chronic constipation.
2009 Dec
Translating 5-HT receptor pharmacology.
2009 Dec
Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study.
2009 Dec
Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.
2009 Feb 1
Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach.
2009 Jan
Motility: prucalopride for chronic constipation.
2009 Jun
Gateways to clinical trials.
2009 Mar
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.
2009 Mar
The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
2009 May
Investigations into the binding affinities of different human 5-HT4 receptor splice variants.
2010
Comments on tegaserod trial on irritable bowel syndrome.
2010 Apr
Effect of ICU interventions on gastrointestinal motility.
2010 Apr
Update on the management of constipation in the elderly: new treatment options.
2010 Aug 9
Prucalopride for constipation.
2010 Feb
Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation.
2010 Feb
Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the rat.
2010 Feb 16
[New drugs for the treatment of constipation].
2010 Jul
New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
2010 Jun
Psychometric evaluation of a visual analog scale for the assessment of anxiety.
2010 Jun 8
Hyperfunction of muscarinic receptor maintains long-term memory in 5-HT4 receptor knock-out mice.
2010 Mar 4
Influence of 5-HT4 receptor activation on acetylcholine release in human large intestine with endometriosis.
2010 May
Emerging pharmacologic therapies for irritable bowel syndrome.
2010 Oct
Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation.
2010 Oct
Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation.
2010 Sep
A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation.
2010 Sep
Patents

Patents

Sample Use Guides

Adults: 2 mg once daily with or without food, at any time of the day.
Route of Administration: Oral
Cell shortening and real-time Ca(2+) measurements were processed on field-stimulated intact cardiomyocytes with the selective 5-HT4R agonist, prucalopride (1 uM).
Substance Class Chemical
Created
by admin
on Sat Dec 16 06:14:35 GMT 2023
Edited
by admin
on Sat Dec 16 06:14:35 GMT 2023
Record UNII
M8IYX9Z79V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PRUCALOPRIDE HYDROCHLORIDE
MART.   WHO-DD  
Common Name English
Prucalopride hydrochloride [WHO-DD]
Common Name English
4-AMINO-5-CHLORO-2,3-DIHYDRO-N-(1-(3-METHOXYPROPYL)-4-PIPERIDINYL)-7-BENZOFURANCARBOXAMIDE HYDROCHLORIDE
Systematic Name English
PRUCALOPRIDE HYDROCHLORIDE [MART.]
Common Name English
Code System Code Type Description
PUBCHEM
9931054
Created by admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
PRIMARY
EVMPD
SUB79171
Created by admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
PRIMARY
FDA UNII
M8IYX9Z79V
Created by admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
PRIMARY
CAS
179474-80-7
Created by admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
PRIMARY
DRUG BANK
DBSALT002348
Created by admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
PRIMARY
SMS_ID
100000138838
Created by admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
PRIMARY
EPA CompTox
DTXSID40170812
Created by admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY